Objective: To systematically evaluate the efficacy and safety of Zhengan Xifeng Tang in treating parkinson disease (PD). Method: All randomized controlled trials (RCTs) of Zhengan Xifeng Tang for treatment of PD were searched from the main Chinese and English medical databases. The assessment tool of bias risk in Cochrane Handbook 5.1.0 software was used to evaluate the bias risks in included literature

and RevMan 5.3 software was applied for statistics and Meta-analysis. In addition

the quality of evidences was evaluated by GRADE profile software. Result: Six studies involving 498 cases were included. Meta-analysis results showed the change of Unified Parkinson's Disease Rating Scale (UPDRS) scores:Subgroup analysis was performed according to the different intervention measures

Zhengan Xifeng Tang vs Madopa(MD=-9.03

95%CI[-11.83

-6.23])

Zhengan Xifeng Tang combined with Madopa vs Madopa(MD=-5.21

95%CI[-9.52

-0.90]); UPDRS Ⅰ+Ⅱ+Ⅲ scores:Zhengan Xifeng Tang+Madopa

Madopa+western medicine vs Madopa

Madopa+western medicine (MD=-5.21

95%CI[-9.52

-0.90])

with statistically significant differences; UPDRS Ⅱ+Ⅲ scores (MD=-7.18

95%CI[-15.71

1.35])

with no statistically significant differences. Meta-analysis on the effective rate calculated by UPDRS reduction rate showed that. Zhengan Xifeng Tang combined with western medicine vs western medicine alone (RR=1.32

95%CI[1.09

1.61])

with statistically significant differences. Adverse reactions:the adverse events or adverse reactions were reported in 4 RCTs. The GRADE profile showed that the included RCTs had low quality of evidences. Conclusion: Zhengan Xifeng Tang or Zhengan Xifeng Tang combined with Madopa

Madopa+western medicine were more effective than Madopa

and Madopa+western medicine. But due to low methodological quality and the small sample size in this systemic review

the clinicians shall be cautious in clinical decision making.